A citation-based method for searching scientific literature

Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees, Patricia Limousin, Thomas Foltynie. J Clin Invest 2013
Times Cited: 286



Eduardo De Pablo-Fernandez, Raph Goldacre, Julia Pakpoor, Alastair J Noyce, Thomas T Warner. Neurology 2018
Times Cited: 112




List of shared articles



Times cited

Diabetes mellitus and Parkinson's disease: dangerous liaisons between insulin and dopamine.
Angela De Iuliis, Ennio Montinaro, Giuseppe Fatati, Mario Plebani, Carlo Colosimo. Neural Regen Res 2022
2

Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation.
Bruno Dutra Arbo, Lucia Emanueli Schimith, Michele Goulart Dos Santos, Mariana Appel Hort. Eur J Pharmacol 2022
0


Parkinson's Disease and Sugar Intake-Reasons for and Consequences of a Still Unclear Craving.
Julienne Haas, Daniela Berg, Anja Bosy-Westphal, Eva Schaeffer. Nutrients 2022
0


Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities.
Daniella Balduino Victorino, Mariana Nejm, Marcia Guimarães-Marques, Fulvio Alexandre Scorza, Carla Alessandra Scorza. Pharmaceut Med 2021
2

Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists.
Carmen M Labandeira, Arturo Fraga-Bau, David Arias Ron, Ana Muñoz, Gema Alonso-Losada, Antonio Koukoulis, Jesus Romero-Lopez, Ana I Rodriguez-Perez. Front Neuroendocrinol 2021
5

Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress.
Tsu-Kung Lin, Kai-Jung Lin, Hung-Yu Lin, Kai-Lieh Lin, Min-Yu Lan, Pei-Wen Wang, Tzu-Jou Wang, Feng-Sheng Wang, Po-Chin Tsai, Chia-Wei Liou,[...]. Front Mol Neurosci 2021
12

Disease modifying therapies III: Novel targets.
Nirosen Vijiaratnam, Thomas Foltynie. Neuropharmacology 2021
3

Insulin Resistance Promotes Parkinson's Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling.
Chien-Tai Hong, Kai-Yun Chen, Weu Wang, Jing-Yuan Chiu, Dean Wu, Tsu-Yi Chao, Chaur-Jong Hu, Kai-Yin David Chau, Oluwaseun Adebayo Bamodu. Cells 2020
34


The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease.
Julia L Y Cheong, Eduardo de Pablo-Fernandez, Thomas Foltynie, Alastair J Noyce. J Parkinsons Dis 2020
41

Elucidating the Relationship Between Diabetes Mellitus and Parkinson's Disease Using 18F-FP-(+)-DTBZ, a Positron-Emission Tomography Probe for Vesicular Monoamine Transporter 2.
Yanyan Kong, Haicong Zhou, Hu Feng, Junyi Zhuang, Tieqiao Wen, Chencheng Zhang, Bomin Sun, Jiao Wang, Yihui Guan. Front Neurosci 2020
4

Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
Ruth Brauer, Li Wei, Tiantian Ma, Dilan Athauda, Christine Girges, Nirosen Vijiaratnam, Grace Auld, Cate Whittlesea, Ian Wong, Tom Foltynie. Brain 2020
45


Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
Andre F Batista, Victor Bodart-Santos, Fernanda G De Felice, Sergio T Ferreira. CNS Drugs 2019
33